PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32040442-2 2020 However, with the increasing application of statins which mainly decrease low-density lipoprotein cholesterol (LDL-C) levels, clinical trials and meta-analysis showed a clearly increase of the incidence of new-onset DMs, partly due to genetic factors. Simvastatin 44-51 component of oligomeric golgi complex 2 Homo sapiens 111-116 31955599-3 2020 Adherence to statins and ezetimibe correlate with LDL-C reduction and risk, potentially accounting for approximately 12 000 avoidable cardiovascular events per 500 000 patients annually (1). Simvastatin 13-20 component of oligomeric golgi complex 2 Homo sapiens 50-55 2634479-6 1989 Long-term simvastatin treatment was well tolerated (lack of important side effects as well as of significant changes of other clinical and laboratory parameters) and effective, reducing significantly (p less than 0.01) TC (317.9 +/- 30.8 vs 238.5 +/- 37.9 mg/dl), LDLc (210.6 +/- 48 vs 147.9 +/- 52 mg/dl), ApoB (144.7 +/- 17.5 vs 104.5 +/- 18), and TG (272.9 +/- 184 vs 200.5 +/- 117.6 mg/dl) and increasing in contrast HDL and ApoA values. Simvastatin 10-21 component of oligomeric golgi complex 2 Homo sapiens 264-268 31957803-1 2020 The current main treatment for coronary artery disease (CAD) is to reduce low-density lipoprotein cholesterol (LDL-C) by statins, which could decrease the incidence of major adverse cardiovascular events (MACEs) by 30%. Simvastatin 121-128 component of oligomeric golgi complex 2 Homo sapiens 111-116 28599257-6 2017 The odds to treat to LDL-C target was greater for simvastatin-ezetimibe fixed combination, simvastatin, atorvastatin and rosuvastatin, in decreasing order. Simvastatin 50-61 component of oligomeric golgi complex 2 Homo sapiens 21-26 31886861-7 2021 Statin dosage, normalized to simvastatin 40 mg, increased from 50 to 58 mg/day (P < 0.0001), and was paralleled by a mean decrease of LDL-C from 97 to 82 mg/dL (P < 0.0001). Simvastatin 0-6 component of oligomeric golgi complex 2 Homo sapiens 137-142 29233637-6 2018 A combination of simvastatin 40 mg daily and ezetimibe 10 mg daily resulted in 57% lowering of LDL-C. Simvastatin 17-28 component of oligomeric golgi complex 2 Homo sapiens 95-100 28711708-7 2017 Ezetimibe and simvastatin combination treatment lowered fasting total cholesterol, LDLc and Lp(a) concentrations and Apo B/A1 ratio and suppressed the MNC expression of IL-1beta and CD68 (by 21 +- 7 and 24 +- 10, p < 0.05) and the concentrations of LPS, CRP, FFA and IL-18 by 24 +- 7%, 32 +- 11%, 19 +- 8% 15 +- 4%, respectively, (p < 0.05). Simvastatin 14-25 component of oligomeric golgi complex 2 Homo sapiens 83-87 31861037-1 2019 Statins therapy decrease both low-density lipoprotein cholesterol (LDL-C) levels and the risk of atherosclerotic cardiovascular disease (ASCVD) with considerable individual variability. Simvastatin 0-7 component of oligomeric golgi complex 2 Homo sapiens 30-65 31861037-1 2019 Statins therapy decrease both low-density lipoprotein cholesterol (LDL-C) levels and the risk of atherosclerotic cardiovascular disease (ASCVD) with considerable individual variability. Simvastatin 0-7 component of oligomeric golgi complex 2 Homo sapiens 67-72 28599257-6 2017 The odds to treat to LDL-C target was greater for simvastatin-ezetimibe fixed combination, simvastatin, atorvastatin and rosuvastatin, in decreasing order. Simvastatin 91-102 component of oligomeric golgi complex 2 Homo sapiens 21-26 28291866-1 2017 Importance: In the Improved Reduction of Outcomes: Vytorin Efficacy International Trial, intensive low-density lipoprotein cholesterol (LDL-C)-reducing therapy with ezetimibe/simvastatin compared with simvastatin alone was associated with a significant reduction in cardiovascular events in 18 144 patients after acute coronary syndrome. Simvastatin 175-186 component of oligomeric golgi complex 2 Homo sapiens 136-141 28291866-1 2017 Importance: In the Improved Reduction of Outcomes: Vytorin Efficacy International Trial, intensive low-density lipoprotein cholesterol (LDL-C)-reducing therapy with ezetimibe/simvastatin compared with simvastatin alone was associated with a significant reduction in cardiovascular events in 18 144 patients after acute coronary syndrome. Simvastatin 201-212 component of oligomeric golgi complex 2 Homo sapiens 136-141 28291866-10 2017 Patients with LDL-C values less than 30 mg/dL (median, 25 mg/dL; interquartile range, 21-27 mg/dL) at 1 month were more likely randomized to ezetimibe/simvastatin (85%), had lower baseline LDL-C values, and were more likely older, male, nonwhite, diabetic, overweight, statin naive, and presenting with a first myocardial infarction. Simvastatin 151-162 component of oligomeric golgi complex 2 Homo sapiens 14-19 24662777-12 2014 Part of these differential effects may be due to the stronger LDL-C-lowering effects of simvastatin. Simvastatin 88-99 component of oligomeric golgi complex 2 Homo sapiens 62-67 27454615-7 2016 Logistic regression analysis showed that female gender, diabetes, and obesity were negative factors, whereas life-style modification and use of high-dose statin (40mg/d simvastatin equivalent) were favorable factors in predicting LDL-C target attainment in the primary care setting. Simvastatin 169-180 component of oligomeric golgi complex 2 Homo sapiens 230-235 26032258-7 2015 KEY FINDINGS: Simvastatin therapy improved the main parameters of lipid metabolism, including statistically significant (P < 0.05) reductions in TC (by 46%) and LDL-C (by 42%), and decreased inflammatory marker C-RP (by 32%), as compared with the baseline. Simvastatin 14-25 component of oligomeric golgi complex 2 Homo sapiens 164-169 25463129-6 2014 RESULTS: LDL-C percent change from baseline was -26.0 for ezetimibe added to ongoing statin therapy, -27.6 for switching from ongoing statin to ezetimibe/simvastatin, -19.7 for switching to rosuvastatin 10 mg, and -9.7 for dose doubling of the ongoing statin. Simvastatin 154-165 component of oligomeric golgi complex 2 Homo sapiens 9-14 25463129-7 2014 For patients within 0.8 mmol/L (30 mg/dL) of the target at baseline, LDL-C target attainment rates were 75.9% for adding ezetimibe to ongoing statin, 72.8% for switching to ezetimibe/simvastatin, 61.8% for switching to rosuvastatin, and 44.3% for statin dose-doubling. Simvastatin 183-194 component of oligomeric golgi complex 2 Homo sapiens 69-74 25066560-3 2014 The simvastatin monotherapy arm"s LDL-C target is <70 mg/dL. Simvastatin 4-15 component of oligomeric golgi complex 2 Homo sapiens 34-39 25089134-11 2014 The differences in the effect of simvastatin on total cholesterol and LDL-C between the patients with and without ezetimibe showed borderline significance (p=0.10 and p=0.055, respectively). Simvastatin 33-44 component of oligomeric golgi complex 2 Homo sapiens 70-75 26638446-9 2015 The addition of ezetimibe to simvastatin resulted in an incremental lowering of LDL-C (reached value 53.2 versus 69.9 mg/dl, p < 0.001) and a further improvement of the patient prognosis (relative reduction of primary endpoint: -6.4%, p = 0.016). Simvastatin 29-40 component of oligomeric golgi complex 2 Homo sapiens 80-85 23776861-9 2013 Following Simvastatin (Simvor) treatment, the mean LDL-C value was reduced by 16%, TCHOL by 23%, TG by 6% and HDL-C increased by 10%. Simvastatin 10-21 component of oligomeric golgi complex 2 Homo sapiens 51-56 24528691-0 2014 Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease. Simvastatin 70-81 component of oligomeric golgi complex 2 Homo sapiens 116-121 24528691-7 2014 LDL-C reduction from baseline and attainment of LDL-C <100 and <70 mg/dL were substantially greater for patients who switched to ezetimibe/simvastatin therapy (-24.0%, 81.2%, and 35.2%, respectively) than for patients who titrated (-9.6%, 68.0%, and 18.4%, respectively) or remained on initial statin therapy (4.9%, 72.2%, and 23.7%, respectively). Simvastatin 145-156 component of oligomeric golgi complex 2 Homo sapiens 0-5 24528691-7 2014 LDL-C reduction from baseline and attainment of LDL-C <100 and <70 mg/dL were substantially greater for patients who switched to ezetimibe/simvastatin therapy (-24.0%, 81.2%, and 35.2%, respectively) than for patients who titrated (-9.6%, 68.0%, and 18.4%, respectively) or remained on initial statin therapy (4.9%, 72.2%, and 23.7%, respectively). Simvastatin 145-156 component of oligomeric golgi complex 2 Homo sapiens 48-53 24380094-3 2013 To identify the conditions for beneficial effects, this study investigated the response to atorvastatin and simvastatin treatment in type 2 diabetic patients with elevated low-density lipoprotein cholesterol (LDL-C). Simvastatin 108-119 component of oligomeric golgi complex 2 Homo sapiens 209-214 24380094-7 2013 There were significant reductions in LDL-C in both the atorvastatin (37.1%) and simvastatin (34.3%) group after one year of treatment compared with baseline levels. Simvastatin 80-91 component of oligomeric golgi complex 2 Homo sapiens 37-42 23288881-3 2013 Significantly greater reductions in LDL-C occurred when switching to EZ/S versus statin doubling in the overall population and in subjects treated with simvastatin 20 mg or atorvastatin 10 mg (all p < 0.001). Simvastatin 152-163 component of oligomeric golgi complex 2 Homo sapiens 36-41 23100282-3 2013 METHODS AND RESULTS: A genome-wide study of the LDL-C and apolipoprotein B (ApoB) response to 40 mg simvastatin daily was performed in 3895 participants in the Heart Protection Study, and the nine strongest associations were tested in 14 810 additional participants. Simvastatin 100-111 component of oligomeric golgi complex 2 Homo sapiens 48-53 21946898-2 2011 The objective of this study was to investigate whether a new CYP3A4 functional single nucleotide polymorphism (SNP) in intron 6 (CYP3A4*22) modifies the effect of simvastatin on total cholesterol (TOTc) or LDL cholesterol (LDLc) reduction in a population-based cohort study. Simvastatin 163-174 component of oligomeric golgi complex 2 Homo sapiens 206-221 22101558-8 2011 Clinical outcome data with ezetimibe combined with simvastatin have recently become available, and definitive evidence that the incremental LDL-C lowering attributable to the ezetimibe component reduces cardiovascular events beyond simvastatin alone is currently under study. Simvastatin 232-243 component of oligomeric golgi complex 2 Homo sapiens 140-145 24265554-0 2013 Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy. Simvastatin 85-96 component of oligomeric golgi complex 2 Homo sapiens 11-16 24265554-6 2013 In multivariable models, percent change from baseline in LDL-C was -13.1% to -14.8% greater for those who added ezetimibe onto simvastatin, atorvastatin, or rosuvastatin versus those who titrated. Simvastatin 127-138 component of oligomeric golgi complex 2 Homo sapiens 57-62 24265554-7 2013 The odds of attaining LDL-C<1.8 and <2.6 mmol/L (70 and 100 mg/dL) increased by 2.6-3.2-fold and 2.5-3.1-fold, respectively, in patients who added ezetimibe onto simvastatin, atorvastatin, or rosuvastatin versus titrating statins. Simvastatin 168-179 component of oligomeric golgi complex 2 Homo sapiens 22-27 22668755-4 2012 In 247 patients with good adherence, the rs4149081 G>A polymorphism was significantly associated with a 4.6 and 4.0% greater low-density lipoprotein cholesterol (LDL-C) reduction compared with those with wild-type alleles in response to rosuvastatin and simvastatin, respectively (P<0.05 for both). Simvastatin 257-268 component of oligomeric golgi complex 2 Homo sapiens 128-163 22668755-4 2012 In 247 patients with good adherence, the rs4149081 G>A polymorphism was significantly associated with a 4.6 and 4.0% greater low-density lipoprotein cholesterol (LDL-C) reduction compared with those with wild-type alleles in response to rosuvastatin and simvastatin, respectively (P<0.05 for both). Simvastatin 257-268 component of oligomeric golgi complex 2 Homo sapiens 165-170 21946898-2 2011 The objective of this study was to investigate whether a new CYP3A4 functional single nucleotide polymorphism (SNP) in intron 6 (CYP3A4*22) modifies the effect of simvastatin on total cholesterol (TOTc) or LDL cholesterol (LDLc) reduction in a population-based cohort study. Simvastatin 163-174 component of oligomeric golgi complex 2 Homo sapiens 223-227 21946898-4 2011 RESULTS: The CYP3A4*22 allele was associated with a trend towards a stronger simvastatin lipid-lowering response, as reflected by the greater reduction in both TOTc and LDLc levels when compared with homozygous wild type. Simvastatin 77-88 component of oligomeric golgi complex 2 Homo sapiens 169-173 21385244-11 2011 When the LDL-C goal was <70mg/dl (1.81mmol/l), 40.2% simvastatin users was considered appropriate, while 58.6% needed atorvastatin to be prescribed. Simvastatin 56-67 component of oligomeric golgi complex 2 Homo sapiens 9-14 22027793-4 2011 RESULTS: At the end of 12 months, the patients in simvastatin group showed significantly reduced total cholesterol, LDL-C, CRP, TNF-alpha, and (99)Tc(m)-MIBI uptake fraction. Simvastatin 50-61 component of oligomeric golgi complex 2 Homo sapiens 116-121 21699369-15 2011 CONCLUSIONS: A single tablet combination of 10 mg ezetimibe and 20 mg simvastatin in Taiwanese patients with hypercholesterolemia provided high LDL-C goal attainment rates and resulted in significant reductions in LDL-C. Simvastatin 70-81 component of oligomeric golgi complex 2 Homo sapiens 144-149 21699369-15 2011 CONCLUSIONS: A single tablet combination of 10 mg ezetimibe and 20 mg simvastatin in Taiwanese patients with hypercholesterolemia provided high LDL-C goal attainment rates and resulted in significant reductions in LDL-C. Simvastatin 70-81 component of oligomeric golgi complex 2 Homo sapiens 214-219 21349260-0 2011 Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease. Simvastatin 47-58 component of oligomeric golgi complex 2 Homo sapiens 128-143 21349260-4 2011 RESULTS: After switching to ezetimibe/simvastatin or rosuvastatin, the LDL-C and non-HDL-C corresponding to Apo B=0.9 g/L were closer to the more aggressive LDL-C and non-HDL-C goals (1.81 and 2.59 mmol/L, respectively). Simvastatin 38-49 component of oligomeric golgi complex 2 Homo sapiens 71-76 21349260-4 2011 RESULTS: After switching to ezetimibe/simvastatin or rosuvastatin, the LDL-C and non-HDL-C corresponding to Apo B=0.9 g/L were closer to the more aggressive LDL-C and non-HDL-C goals (1.81 and 2.59 mmol/L, respectively). Simvastatin 38-49 component of oligomeric golgi complex 2 Homo sapiens 157-162 21559521-8 2011 CONCLUSIONS: This observational study shows that the LDL-C levels in patients taking simvastatin, atorvastatin or rosuvastatin are very similar as currently used, as well as their LDL-C lowering abilities. Simvastatin 85-96 component of oligomeric golgi complex 2 Homo sapiens 53-58 21559521-8 2011 CONCLUSIONS: This observational study shows that the LDL-C levels in patients taking simvastatin, atorvastatin or rosuvastatin are very similar as currently used, as well as their LDL-C lowering abilities. Simvastatin 85-96 component of oligomeric golgi complex 2 Homo sapiens 180-185 21271793-6 2011 The changes in total cholesterol, LDL-C and non-HDL-C were greater in the simvastatin/ezetimibe group (all p < 0.05). Simvastatin 74-85 component of oligomeric golgi complex 2 Homo sapiens 34-39 21497705-0 2011 Combination therapy with ezetimibe/simvastatin versus statin monotherapy for low-density lipoprotein cholesterol reduction and goal attainment in a real-world clinical setting. Simvastatin 35-46 component of oligomeric golgi complex 2 Homo sapiens 77-112 21519514-2 2011 The aim of this study is to compare the effect of ezetimibe/simvastatin 10/20 mg and atorvastatin 20 mg on achieving a target LDL-C goal in very high risk patients. Simvastatin 60-71 component of oligomeric golgi complex 2 Homo sapiens 126-131 21519514-11 2011 CONCLUSION: Ezetimibe/simvastatin 10/20 mg and atorvastatin 20 mg showed similar effects in achieving target LDL-C levels in patients with very high risk. Simvastatin 22-33 component of oligomeric golgi complex 2 Homo sapiens 109-114 21497705-3 2011 Data to support the LDL-C lowering efficacy of ezetimibe/simvastatin (EZE/SMV) outside of controlled clinical studies are currently lacking. Simvastatin 57-68 component of oligomeric golgi complex 2 Homo sapiens 20-25 21122696-2 2010 OBJECTIVE: To assess the impact of switches from high-efficacy lipid-lowering therapy to simvastatin on low-density lipoprotein cholesterol (LDL-C) and goal attainment in coronary heart disease (CHD) or CHD risk-equivalent patients in a managed care setting. Simvastatin 89-100 component of oligomeric golgi complex 2 Homo sapiens 141-146 20519697-7 2011 In the simvastatin treatment group, the percentage reduction of LDL-C level was greater in the CYP3AP1*3/*3 carriers than in the CYP3AP1*1 carriers. Simvastatin 7-18 component of oligomeric golgi complex 2 Homo sapiens 64-69 21189431-11 2011 Effects of atorvastatin and simvastatin on the LDLC levels were significant, while lovastatin had a marginal effect. Simvastatin 28-39 component of oligomeric golgi complex 2 Homo sapiens 47-51 21189431-15 2011 However, simvastatin had the greatest impact on LDLC. Simvastatin 9-20 component of oligomeric golgi complex 2 Homo sapiens 48-52 21122696-5 2010 The difference in percent change in LDL-C levels from baseline were 25.2 (95% confidence interval 21.2-29.2), 13.0 (6.0-20.0), and 3.1 (0.3-5.9) greater in switchers to simvastatin in the E/S, rosuvastatin, and atorvastatin comparisons, respectively, after adjusting for age, sex, and starting dose of the initial therapy. Simvastatin 169-180 component of oligomeric golgi complex 2 Homo sapiens 36-41 21122696-8 2010 CONCLUSIONS: Among CHD/CHD risk-equivalent patients, switching to simvastatin was associated with increases in LDL-C levels and lower LDL-C goal attainment rates. Simvastatin 66-77 component of oligomeric golgi complex 2 Homo sapiens 111-116 21122696-8 2010 CONCLUSIONS: Among CHD/CHD risk-equivalent patients, switching to simvastatin was associated with increases in LDL-C levels and lower LDL-C goal attainment rates. Simvastatin 66-77 component of oligomeric golgi complex 2 Homo sapiens 134-139 20941469-9 2010 Whether the strong LDL-C lowering combination of simvastatin plus ezetimibe will reduce cardiovascular events over and above simvastatin monotherapy is currently being tested in the ongoing IMPROVE-IT trial. Simvastatin 49-60 component of oligomeric golgi complex 2 Homo sapiens 19-24 20653799-1 2010 BACKGROUND: The introduction of a generic formulation of simvastatin has created the potential to provide significant low-density lipoprotein cholesterol (LDL-C) reduction in a highly cost-effective manner. Simvastatin 57-68 component of oligomeric golgi complex 2 Homo sapiens 118-153 20653799-1 2010 BACKGROUND: The introduction of a generic formulation of simvastatin has created the potential to provide significant low-density lipoprotein cholesterol (LDL-C) reduction in a highly cost-effective manner. Simvastatin 57-68 component of oligomeric golgi complex 2 Homo sapiens 155-160 20602615-1 2010 AIM: Administered at maximal dosages, the most common statins--atorvastatin, simvastatin and rosuvastatin--lower low-density lipoprotein cholesterol (LDLC) by an average of 37-57% in patients with primary hypercholesterolemia. Simvastatin 77-88 component of oligomeric golgi complex 2 Homo sapiens 150-154 20487050-8 2010 In this group, treatment with ezetimibe/simvastatin 10/40 mg achieved target LDL-C levels in a significantly higher proportion of patients during a 6-week period than switching to either atorvastatin 40 mg or rosuvastatin 5-10 mg. Simvastatin 40-51 component of oligomeric golgi complex 2 Homo sapiens 77-82 19770794-0 2010 Switching from atorvastatin to simvastatin in patients at high cardiovascular risk: effects on low-density lipoprotein cholesterol. Simvastatin 31-42 component of oligomeric golgi complex 2 Homo sapiens 95-130 19770794-7 2010 Switched patients who were not prescribed a higher milligram dose of simvastatin were significantly less likely to reach an LDL-C less than 100 mg/dL (62.3% versus 74.0%; odds ratio, 0.55; 95% confidence interval, 0.36-0.84; P = 0.006) and had higher LDL-C (95.1 versus 87.2 mg/dL; P = 0.002) than control subjects. Simvastatin 69-80 component of oligomeric golgi complex 2 Homo sapiens 124-129 19770794-8 2010 A large proportion of patients who switch from atorvastatin to simvastatin are prescribed doses that are not therapeutically equivalent, and these patients were significantly less likely to meet LDL-C treatment goals compared with patients who remained on atorvastatin. Simvastatin 63-74 component of oligomeric golgi complex 2 Homo sapiens 195-200 19770794-2 2010 We examined the association between switching from atorvastatin to simvastatin and changes in low-density lipoprotein cholesterol (LDL-C) levels in clinical practice. Simvastatin 67-78 component of oligomeric golgi complex 2 Homo sapiens 94-129 19770794-2 2010 We examined the association between switching from atorvastatin to simvastatin and changes in low-density lipoprotein cholesterol (LDL-C) levels in clinical practice. Simvastatin 67-78 component of oligomeric golgi complex 2 Homo sapiens 131-136 19997842-4 2009 RESULTS: During the follow-up period of 4-12 weeks, LDL-C levels were reduced by a median of 27-31% of baseline values (mean 153.1 +/- 33.5 mg/dl) mainly regardless of previous statin therapy (rosuvastatin, atorvastatin, simvastatin, pravastatin, fluvastatin, and lovastatin) and dosing (pooled median values). Simvastatin 221-232 component of oligomeric golgi complex 2 Homo sapiens 52-57 20203452-14 2010 Patients switched to an equivalent simvastatin dose had lower LDL-C levels and were more likely to achieve LDL-C targets than patients switched to a non-equivalent dose, suggesting physicians must consider dosage equivalence when switching statins, and should measure LDL-C and titrate statins as necessary to achieve LDL-C control. Simvastatin 35-46 component of oligomeric golgi complex 2 Homo sapiens 62-67 20203452-14 2010 Patients switched to an equivalent simvastatin dose had lower LDL-C levels and were more likely to achieve LDL-C targets than patients switched to a non-equivalent dose, suggesting physicians must consider dosage equivalence when switching statins, and should measure LDL-C and titrate statins as necessary to achieve LDL-C control. Simvastatin 35-46 component of oligomeric golgi complex 2 Homo sapiens 107-112 20203452-14 2010 Patients switched to an equivalent simvastatin dose had lower LDL-C levels and were more likely to achieve LDL-C targets than patients switched to a non-equivalent dose, suggesting physicians must consider dosage equivalence when switching statins, and should measure LDL-C and titrate statins as necessary to achieve LDL-C control. Simvastatin 35-46 component of oligomeric golgi complex 2 Homo sapiens 107-112 20203452-14 2010 Patients switched to an equivalent simvastatin dose had lower LDL-C levels and were more likely to achieve LDL-C targets than patients switched to a non-equivalent dose, suggesting physicians must consider dosage equivalence when switching statins, and should measure LDL-C and titrate statins as necessary to achieve LDL-C control. Simvastatin 35-46 component of oligomeric golgi complex 2 Homo sapiens 107-112 21348380-8 2010 The combination of ezetimibe and low-dose simvastatin significantly reduced levels of total cholesterol (by a mean of 27%), triglycerides (by 9%), and LDL-C (by 33%) and increased levels of high-density lipoprotein cholesterol (by 15%). Simvastatin 42-53 component of oligomeric golgi complex 2 Homo sapiens 151-156 21090830-14 2010 Simvastatin was the most cost-effective statin to achieve the LDL-C goal in patients with moderate or low CHD risk, with a cost per patient of Euro 217 and Euro 190, respectively. Simvastatin 0-11 component of oligomeric golgi complex 2 Homo sapiens 62-67 19916706-0 2010 Therapy modifications and low-density lipoprotein cholesterol goal attainment rates associated with the initiation of generic simvastatin. Simvastatin 126-137 component of oligomeric golgi complex 2 Homo sapiens 26-61 19721860-6 2009 RESULTS: Ezetimibe and low-dose simvastatin significantly decreased the levels of total cholesterol (34.6%), triglyceride (16.0%), and low-density lipoprotein cholesterol (LDL-C) (47.6%), and 82.5% of the patients reached the target LDL-C level of <100 mg/dL. Simvastatin 32-43 component of oligomeric golgi complex 2 Homo sapiens 135-170 19721860-6 2009 RESULTS: Ezetimibe and low-dose simvastatin significantly decreased the levels of total cholesterol (34.6%), triglyceride (16.0%), and low-density lipoprotein cholesterol (LDL-C) (47.6%), and 82.5% of the patients reached the target LDL-C level of <100 mg/dL. Simvastatin 32-43 component of oligomeric golgi complex 2 Homo sapiens 172-177 19721860-6 2009 RESULTS: Ezetimibe and low-dose simvastatin significantly decreased the levels of total cholesterol (34.6%), triglyceride (16.0%), and low-density lipoprotein cholesterol (LDL-C) (47.6%), and 82.5% of the patients reached the target LDL-C level of <100 mg/dL. Simvastatin 32-43 component of oligomeric golgi complex 2 Homo sapiens 233-238 20203452-0 2010 LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice. Simvastatin 112-123 component of oligomeric golgi complex 2 Homo sapiens 0-5 19965915-7 2010 RESULTS: LDL-C levels were reduced by 19% (ezetimibe), 25% (simvastatin), and 41% (ezetimibe+simvastatin) from a baseline of 146 +/- 20 mg/dl; results were similar between ethnic groups. Simvastatin 60-71 component of oligomeric golgi complex 2 Homo sapiens 9-14 19965915-7 2010 RESULTS: LDL-C levels were reduced by 19% (ezetimibe), 25% (simvastatin), and 41% (ezetimibe+simvastatin) from a baseline of 146 +/- 20 mg/dl; results were similar between ethnic groups. Simvastatin 93-104 component of oligomeric golgi complex 2 Homo sapiens 9-14 19965915-9 2010 Although individual responses varied widely, change in LDL-C on ezetimibe correlated with response to simvastatin (r = 0.46, P < 0.001). Simvastatin 102-113 component of oligomeric golgi complex 2 Homo sapiens 55-60 19745745-4 2009 There were statistically significant differences for simvastatin versus rosuvastatin, respectively, for mean LDLc 2.03 mmol/l (78 mg/dl) versus 1.94 mmol/l (75 mg/dl; P = 0.009) and also mean TC 3.88 mmol/l (150 mg/dl) versus 3.75 mmol/l (145 mg/dl; P = 0.005). Simvastatin 53-64 component of oligomeric golgi complex 2 Homo sapiens 109-113 19997842-5 2009 LDL-C reduction correlated proportional with baseline LDL-C values and increased with increasing simvastatin dosage. Simvastatin 97-108 component of oligomeric golgi complex 2 Homo sapiens 0-5 19997842-7 2009 CONCLUSIONS: The fixed combination therapy with ezetimibe/simvastatin showed a clinically significant additional lipid-lowering potential as compared with established statin monotherapies and enabled more patients at cardiovascular risk to reach the LDL-C target level of <100 mg/dl. Simvastatin 58-69 component of oligomeric golgi complex 2 Homo sapiens 250-255 19014834-13 2008 CONCLUSIONS: In these patients with hypertension and hypercholesterolemia, coadministration of valsartan and simvastatin was well tolerated and was associated with significant reductions from baseline in BP and LDL-C. Simvastatin 109-120 component of oligomeric golgi complex 2 Homo sapiens 211-216 19014834-14 2008 Coadministered with valsartan 160/320 mg in the evening, simvastatin 40 mg had superior LDL-C-lowering efficacy to simvastatin 20 mg. Simvastatin 57-68 component of oligomeric golgi complex 2 Homo sapiens 88-93 18578957-6 2008 Average LDL-C reductions were 48%, 42%, 39%, and 32% at mean doses of 11 mg rosuvastatin, 17 mg atorvastatin, 22 mg simvastatin and 35 mg pravastatin, respectively. Simvastatin 116-127 component of oligomeric golgi complex 2 Homo sapiens 8-13 18332269-6 2008 These single nucleotide polymorphisms and the common haplotypes inferred from them were tested for association with plasma LDL-C and LDL-C response to simvastatin treatment (40 mg/d for 6 weeks) in 326 blacks and 596 whites. Simvastatin 151-162 component of oligomeric golgi complex 2 Homo sapiens 133-138 18332269-10 2008 CONCLUSIONS: HMGCR gene polymorphisms are associated with reduced plasma LDL-C and LDL-C response to simvastatin, and these effects are most evident in blacks. Simvastatin 101-112 component of oligomeric golgi complex 2 Homo sapiens 83-88 18226326-8 2008 CONCLUSIONS: In CHD/DM2 patients treated with simvastatin or atorvastatin with LDL-C persistently > or = 2.5 mmol/L, switching to the EZE/SIMVA was more effective in attaining the LDL-C target of < 2.5 mmol/L than doubling the statin dose. Simvastatin 46-57 component of oligomeric golgi complex 2 Homo sapiens 79-84 21291710-0 2008 Efficacy of simvastatin therapy in attainment of LDL-C and TG goal levels in patients with type 2 diabetic dyslipidemia. Simvastatin 12-23 component of oligomeric golgi complex 2 Homo sapiens 49-54 21291710-2 2008 OBJECTIVE: To evaluate the efficacy of simvastatin (S) in achieving LDL-C levels <70 mg/dL in patients with type 2 diabetes mellitus (DM). Simvastatin 39-50 component of oligomeric golgi complex 2 Homo sapiens 68-73 21291712-0 2008 Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non-HDL-C, ApoB, and hs-CRP in patients with type 2 diabetes. Simvastatin 20-31 component of oligomeric golgi complex 2 Homo sapiens 70-75 17577472-0 2007 A model for assessing the cost-effectiveness of atorvastatin and simvastatin in achieving Canadian low-density lipoprotein cholesterol targets. Simvastatin 65-76 component of oligomeric golgi complex 2 Homo sapiens 99-134 17711713-10 2007 RESULTS: Simvastatin treatment reduced low density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) levels and improved endothelial-dependent vasodilation in patients after 4 weeks. Simvastatin 9-20 component of oligomeric golgi complex 2 Homo sapiens 76-81 17711713-12 2007 After terminating simvastatin treatment, serum NO and plasma 6-keto-PGF1(alpha) levels decreased, as well as plasma ET and serum LDL-C levels increased. Simvastatin 18-29 component of oligomeric golgi complex 2 Homo sapiens 129-134 18683797-6 2008 RESULTS: Simvastatin treatment for 4 weeks significantly improved FMD and reduced low density LDL-C and total TC levels. Simvastatin 9-20 component of oligomeric golgi complex 2 Homo sapiens 94-99 17577472-4 2007 OBJECTIVE: This analysis compared the cost-effectiveness of atorvastatin and generic simvastatin in terms of annual drug cost per patient treated to Canadian LDL-C targets. Simvastatin 85-96 component of oligomeric golgi complex 2 Homo sapiens 158-163 17577472-7 2007 Canadian data on statin dosing were combined with efficacy data from a published meta-analysis to determine the proportion of patients who would be expected to achieve LDL-C targets after treatment with atorvastatin or generic simvastatin. Simvastatin 227-238 component of oligomeric golgi complex 2 Homo sapiens 168-173 17577472-10 2007 RESULTS: The model predicted that more patients would reach the LDL-C target with atorvastatin than with simvastatin (73% vs 57%, respectively). Simvastatin 105-116 component of oligomeric golgi complex 2 Homo sapiens 64-69 17084257-10 2006 Simvastatin reduced low-density lipoprotein cholesterol (LDL-C) by 30% (p < 0.01) and increased high-density lipoprotein cholesterol (HDL-C) by 15% (p < 0.01), whereas LDL-C and HDL-C levels were not changed in the diet group. Simvastatin 0-11 component of oligomeric golgi complex 2 Homo sapiens 20-55 17084257-10 2006 Simvastatin reduced low-density lipoprotein cholesterol (LDL-C) by 30% (p < 0.01) and increased high-density lipoprotein cholesterol (HDL-C) by 15% (p < 0.01), whereas LDL-C and HDL-C levels were not changed in the diet group. Simvastatin 0-11 component of oligomeric golgi complex 2 Homo sapiens 57-62 17084257-10 2006 Simvastatin reduced low-density lipoprotein cholesterol (LDL-C) by 30% (p < 0.01) and increased high-density lipoprotein cholesterol (HDL-C) by 15% (p < 0.01), whereas LDL-C and HDL-C levels were not changed in the diet group. Simvastatin 0-11 component of oligomeric golgi complex 2 Homo sapiens 174-179 17084257-13 2006 The LDL-C-independent effects of simvastatin may participate in the beneficial effect. Simvastatin 33-44 component of oligomeric golgi complex 2 Homo sapiens 4-9 17112329-8 2006 Adjusted for baseline factors, percent LDL-C reduction was significantly greater with rosuvastatin versus atorvastatin or simvastatin (37% vs 28% or 27%, respectively; P <.05). Simvastatin 122-133 component of oligomeric golgi complex 2 Homo sapiens 39-44 16893434-5 2006 Moreover, a higher proportion of patients on ezetimibe/simvastatin achieved the National Standard Framework LDL-C standard (<3.0 mmol/l; 93% vs. 75%, p < 0.001) or the new Joint British Societies (JBS 2) goal of LDL-C < 2.0 mmol/l (49.3% vs. 11.1%, p < 0.001). Simvastatin 55-66 component of oligomeric golgi complex 2 Homo sapiens 108-113 16893434-4 2006 At 6 weeks, ezetimibe 10 mg-simvastatin 20 mg provided a mean additional LDL-C reduction of 14.6% (95% CI 10.1-19.1) compared with simvastatin monotherapy (p < 0.0001). Simvastatin 28-39 component of oligomeric golgi complex 2 Homo sapiens 73-78 16893434-5 2006 Moreover, a higher proportion of patients on ezetimibe/simvastatin achieved the National Standard Framework LDL-C standard (<3.0 mmol/l; 93% vs. 75%, p < 0.001) or the new Joint British Societies (JBS 2) goal of LDL-C < 2.0 mmol/l (49.3% vs. 11.1%, p < 0.001). Simvastatin 55-66 component of oligomeric golgi complex 2 Homo sapiens 218-223 16893434-6 2006 On logistic regression analysis, the odds ratio of achieving target LDL-C with ezetimibe 10 mg-simvastatin 20 mg was 5.1 (95% CI 1.8-15.0) times higher than with simvastatin monotherapy (p = 0.003). Simvastatin 95-106 component of oligomeric golgi complex 2 Homo sapiens 68-73 16893434-6 2006 On logistic regression analysis, the odds ratio of achieving target LDL-C with ezetimibe 10 mg-simvastatin 20 mg was 5.1 (95% CI 1.8-15.0) times higher than with simvastatin monotherapy (p = 0.003). Simvastatin 162-173 component of oligomeric golgi complex 2 Homo sapiens 68-73 16799230-3 2006 Simvastatin reduced serum low-density lipoprotein cholesterol (LDL-C) by 27% in both genders, and increased serum high-density lipoprotein cholesterol (HDL-C) in men (5%) and women (4%). Simvastatin 0-11 component of oligomeric golgi complex 2 Homo sapiens 26-61 16799230-3 2006 Simvastatin reduced serum low-density lipoprotein cholesterol (LDL-C) by 27% in both genders, and increased serum high-density lipoprotein cholesterol (HDL-C) in men (5%) and women (4%). Simvastatin 0-11 component of oligomeric golgi complex 2 Homo sapiens 63-68 15324535-10 2004 RESULTS: Simvastatin treatment significantly reduced serum cholesterol, LDL-cholesterol (LDL-C) and apolipoprotein (apo) B levels (p < 0.001). Simvastatin 9-20 component of oligomeric golgi complex 2 Homo sapiens 89-122 16574035-8 2006 The LDL-C-lowering efficacy of targeting both major sources of cholesterol with ezetimibe plus simvastatin was demonstrated in several multicentre, double-blind, placebo-controlled trials in patients with hypercholesterolaemia. Simvastatin 95-106 component of oligomeric golgi complex 2 Homo sapiens 4-9 17319467-6 2006 This article reviews the implications of the updated guidelines and discusses the efficacy and safety of ezetimibe/simvastatin for lowering LDL-C. Simvastatin 115-126 component of oligomeric golgi complex 2 Homo sapiens 140-145 15864235-2 2005 This study tested the hypothesis that ezetimibe/simvastatin, a lipid-lowering agent that inhibits both intestinal cholesterol absorption and cholesterol synthesis, provides greater LDL-C reductions than atorvastatin across dose ranges. Simvastatin 48-59 component of oligomeric golgi complex 2 Homo sapiens 181-186 15864235-5 2005 RESULTS: At each milligram-equivalent statin dose comparison, and averaged across doses, ezetimibe/simvastatin provided greater LDL-C reductions (47%-59%) than atorvastatin (36%-53%). Simvastatin 99-110 component of oligomeric golgi complex 2 Homo sapiens 128-133 16369229-0 2005 LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD. Simvastatin 42-53 component of oligomeric golgi complex 2 Homo sapiens 0-5 16369229-7 2005 The percentage reaching the optional LDL-C treatment target of < 70 mg/dL was also significantly higher with EZE/SIMVA compared with either atorvastatin or simvastatin. Simvastatin 159-170 component of oligomeric golgi complex 2 Homo sapiens 37-42 15864235-7 2005 More ezetimibe/simvastatin than atorvastatin patients with coronary heart disease (CHD) or CHD risk equivalents attained the ATP III LDL-C goal of <100 mg/dL and the optional LDL-C target of <70 mg/dL. Simvastatin 15-26 component of oligomeric golgi complex 2 Homo sapiens 133-138 15864235-7 2005 More ezetimibe/simvastatin than atorvastatin patients with coronary heart disease (CHD) or CHD risk equivalents attained the ATP III LDL-C goal of <100 mg/dL and the optional LDL-C target of <70 mg/dL. Simvastatin 15-26 component of oligomeric golgi complex 2 Homo sapiens 178-183 15864235-11 2005 CONCLUSIONS: Ezetimibe/simvastatin was more effective than atorvastatin in lowering LDL-C at each dose comparison and provided greater increases in HDL-C at the 40- and 80-mg statin dose. Simvastatin 23-34 component of oligomeric golgi complex 2 Homo sapiens 84-89 12774855-12 2003 Simvastatin and pravastatin reduced the total cholesterol concentration and LDL-cholesterol in plasma, as well as the cholesterol concentration in erythrocytes membranes. Simvastatin 0-11 component of oligomeric golgi complex 2 Homo sapiens 76-91 15132403-6 2004 RESULTS: Coadministration of ezetimibe/simvastatin was significantly (P<.001) more effective than simvastatin alone in reducing LDL-C levels for the pooled ezetimibe/simvastatin vs pooled simvastatin analysis and at each specific dose comparison. Simvastatin 39-50 component of oligomeric golgi complex 2 Homo sapiens 131-136 15132403-7 2004 The decrease in LDL-C levels with coadministration of ezetimibe and the lowest dose of simvastatin, 10 mg, was similar to the decrease with the maximum dose of simvastatin, 80 mg. A significantly (P<.001) greater proportion of patients in the ezetimibe/simvastatin group achieved target LDL-C levels compared with those in the monotherapy group. Simvastatin 87-98 component of oligomeric golgi complex 2 Homo sapiens 16-21 15132403-7 2004 The decrease in LDL-C levels with coadministration of ezetimibe and the lowest dose of simvastatin, 10 mg, was similar to the decrease with the maximum dose of simvastatin, 80 mg. A significantly (P<.001) greater proportion of patients in the ezetimibe/simvastatin group achieved target LDL-C levels compared with those in the monotherapy group. Simvastatin 87-98 component of oligomeric golgi complex 2 Homo sapiens 290-295 15334157-11 2004 The addition of simvastatin to fenofibrate decreased TC, LDL-C and TG levels by 35.5%, 42.1% and 59.6%, respectively in comparison to before treatment volumes. Simvastatin 16-27 component of oligomeric golgi complex 2 Homo sapiens 57-62 15334157-13 2004 The addition of fenofibrate to simvastatin decreased TC, LDL-C and TG levels by 39.3%, 48.9% and 51,6%, respectively. Simvastatin 31-42 component of oligomeric golgi complex 2 Homo sapiens 57-62 12353340-7 2002 RESULTS: After 8 weeks of treatment, LDL-C concentrations were reduced by 42.5% from baseline in patients receiving atorvastatin and 34.8% in those receiving simvastatin (p = 0.0006). Simvastatin 158-169 component of oligomeric golgi complex 2 Homo sapiens 37-42 12637115-15 2003 CONCLUSIONS: Atorvastatin 20 or 40 mg/d for up to 1 year of treatment was significantly more effective than simvastatin 20 or 40 mg/d in reducing LDL-C and TG levels and at achieving recommended lipid targets in this selected patient population with cardiovascular disease and dyslipidemia. Simvastatin 108-119 component of oligomeric golgi complex 2 Homo sapiens 146-151 12499611-5 2002 Simvastatin reduced serum concentrations of total cholesterol (TC), low-density lipoprotein- cholesterol (LDL-C) and triglyceride (TG), by 18.4%, 26.8% and 16.1% on average, respectively, during the treatment period. Simvastatin 0-11 component of oligomeric golgi complex 2 Homo sapiens 68-104 12499611-5 2002 Simvastatin reduced serum concentrations of total cholesterol (TC), low-density lipoprotein- cholesterol (LDL-C) and triglyceride (TG), by 18.4%, 26.8% and 16.1% on average, respectively, during the treatment period. Simvastatin 0-11 component of oligomeric golgi complex 2 Homo sapiens 106-111 12353340-11 2002 After 16 weeks of treatment, 93% of atorvastatin and 85% of simvastatin patients had achieved their National Cholesterol Education Program LDL-C goals. Simvastatin 60-71 component of oligomeric golgi complex 2 Homo sapiens 139-144 11383320-1 2001 BACKGROUND AND AIM: This study compares the cholesterol-lowering efficacy of atorvastatin and simvastatin in attainment of the National Cholesterol Education Program (NCEP) guidelines LDL-cholesterol (LDL-C) goal in patients with heterozygous familial hypercholesterolemia (HFH). Simvastatin 94-105 component of oligomeric golgi complex 2 Homo sapiens 184-199 12029990-10 2002 Simvastatin reduced serum concentrations of TC, LDL-C and TG by 18.4, 26.8 and 16.1%, respectively. Simvastatin 0-11 component of oligomeric golgi complex 2 Homo sapiens 48-53 11748098-5 2001 CONCLUSIONS: Patients with elevated LDL-C, low HDL-C, and elevated triglycerides were more likely than patients with isolated LDL-C elevation to have other characteristics of the metabolic syndrome, had increased risk for CHD events on placebo, and received greater benefit with simvastatin therapy. Simvastatin 279-290 component of oligomeric golgi complex 2 Homo sapiens 36-41 11440286-11 2001 Overall, 104 (78.2%) patients treated with simvastatin achieved LDL-C levels < or = 100 mg/dL at week 14, and 125 (94.0%) achieved this target at some point during the study. Simvastatin 43-54 component of oligomeric golgi complex 2 Homo sapiens 64-69 11318080-12 2001 At the end of the study, 60.8% (135/222) of patients in the simvastatin group had reached target LDL-C goals, compared with 35.1% (76/216) in the fluvastatin group (P < 0.001). Simvastatin 60-71 component of oligomeric golgi complex 2 Homo sapiens 97-102 11318080-13 2001 In the simvastatin CHD and MRF subgroups, 49% and 73%, respectively, reached the LDL-C target, compared with 19% and 50% in the corresponding fluvastatin subgroups (P < 0.001). Simvastatin 7-18 component of oligomeric golgi complex 2 Homo sapiens 81-86 11318080-16 2001 CONCLUSION: In this study, more patients with primary hypercholesterolemia and CHD or multiple risk factors for CHD reached LDL-C goals with simvastatin treatment and required less titration than those who received fluvastatin treatment. Simvastatin 141-152 component of oligomeric golgi complex 2 Homo sapiens 124-129 10740137-8 2000 CONCLUSIONS: The use of more potent statins such as atorvastatin and simvastatin affords greater lowering of LDL-C and triglyceride levels, allowing more patients to achieve target goals. Simvastatin 69-80 component of oligomeric golgi complex 2 Homo sapiens 109-114 10101552-7 1998 A greater reduction of LDL-C (32%) was achieved by simvastatin monotherapy. Simvastatin 51-62 component of oligomeric golgi complex 2 Homo sapiens 23-28 9920147-8 1999 Simvastatin treatment reduced circulating TC, LDL-C, and TG by 40%, 50%, and 33% (P<.007), respectively. Simvastatin 0-11 component of oligomeric golgi complex 2 Homo sapiens 46-51 25626487-0 2015 Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom. Simvastatin 75-86 component of oligomeric golgi complex 2 Homo sapiens 90-95 9793596-12 1998 In comparison, currently available HMG-CoA reductase inhibitors (lovastatin, simvastatin, pravastatin, fluvastatin, cerivastatin) lower LDL-C concentrations by approximately 20-40% and TG concentrations by approximately 10-30%. Simvastatin 77-88 component of oligomeric golgi complex 2 Homo sapiens 136-141 10095800-8 1998 RESULTS: LDLc concentration significantly decreased during treatment with 80 mg atorvastatin as compared to LDLc levels on 40 mg simvastatin alone or in combination with 8-12 g colestyramin, by 24 +/- 14% (P < 0.01) and 19 +/- 22% (P < 0.01), respectively. Simvastatin 129-140 component of oligomeric golgi complex 2 Homo sapiens 108-112 18370543-8 1998 RESULTS: Ten of 15 patients on atorvastatin 10mg (66%) and four of 15 on simvastatin 10mg (27%) achieved the LDL-C <130 mg/dl goal. Simvastatin 73-84 component of oligomeric golgi complex 2 Homo sapiens 109-114 18370543-10 1998 During the second 16-week period seven of 11 patients receiving the simvastatin 20mg dose (64%) achieved the LDL-C <130 mg/dl goal. Simvastatin 68-79 component of oligomeric golgi complex 2 Homo sapiens 109-114 9377621-9 1997 Simvastatin 2.5 mg/d reduced LDL-C levels by 22.9% and total-C levels by 15.7%; simvastatin 40 mg/d reduced these levels by 40.7% and 29.7%, respectively. Simvastatin 0-11 component of oligomeric golgi complex 2 Homo sapiens 29-34 7752830-8 1994 This study demonstrates that simvastatin lowers both LDL-C and apo B plasma levels together with the plasma and platelet levels of CoQ10, and that CoQ10 therapy prevents both plasma and platelet CoQ10 decrease, without affecting the cholesterol lowering effect of simvastatin. Simvastatin 29-40 component of oligomeric golgi complex 2 Homo sapiens 53-58 25626487-10 2015 Compared to non-switchers, the adjusted least squares mean differences in the percentage change in LDL-C levels from baseline were 18.74% (p = 0.0003), 16.73% (p < 0.0001), and -0.11% (p = 0.9044) when switching from simvastatin/ezetimibe, rosuvastatin, and atorvastatin, respectively. Simvastatin 220-231 component of oligomeric golgi complex 2 Homo sapiens 99-104 25626487-11 2015 The odds of LDL-C goal attainment at follow-up among switchers from simvastatin/ezetimibe, rosuvastatin, and atorvastatin were 0.40 (95% CI: 0.23-0.70), 0.36 (95% CI: 0.26-0.51) and 1.03 (95% CI: 0.92-1.15) relative to non-switchers respectively. Simvastatin 68-79 component of oligomeric golgi complex 2 Homo sapiens 12-17 25626487-12 2015 IMPLICATIONS: Among the high risk CVD population in UK, switching to simvastatin from HET, especially rosuvastatin and simvastatin/ezetimibe, resulted in an increase in LDL-C levels and lower goal attainment. Simvastatin 69-80 component of oligomeric golgi complex 2 Homo sapiens 169-174 25626487-12 2015 IMPLICATIONS: Among the high risk CVD population in UK, switching to simvastatin from HET, especially rosuvastatin and simvastatin/ezetimibe, resulted in an increase in LDL-C levels and lower goal attainment. Simvastatin 119-130 component of oligomeric golgi complex 2 Homo sapiens 169-174 25626487-2 2015 Switching from high-efficacy lipid-lowering therapies (HETs) to simvastatin might lead to sub-optimal control of LDL-C. Simvastatin 64-75 component of oligomeric golgi complex 2 Homo sapiens 113-118 25626487-3 2015 Our objective was to evaluate the impact of switching from HETs to generic simvastatin on LDL-C levels and LDL-C goal attainment among the high-risk primary and secondary prevention populations in the United Kingdom. Simvastatin 75-86 component of oligomeric golgi complex 2 Homo sapiens 90-95